KuDOS Pharmaceuticals Ltd
AstraZeneca UK is a leading biopharmaceutical company committed to transforming healthcare through science, innovation, and purpose-led partnerships. They focus on delivering life-changing medicines, supporting population health, and advancing UK as a global life sciences hub. Their initiatives include sustainability, purpose-driven partnerships, and investing in communities and talent development.
Industries
Nr. of Employees
small (1-50)
KuDOS Pharmaceuticals Ltd
AstraZeneca UK, [specific address not provided]
Patents
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12178816-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12144810-B1
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12048695-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-11975001-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one
US-11633396-B2
View Details
Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12178816-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12144810-B1
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-12048695-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US-11975001-B2
View DetailsImmediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one
US-11633396-B2
View DetailsProducts
Portfolio of marketed medicines (UK)
A marketed portfolio of prescription medicines across multiple therapy areas with product listings and prescribing information available on national electronic medicines compendia.
Clinical trials disclosure platform
A public-facing clinical trials information platform listing trial registrations and outcomes for transparency and professional access.
Portfolio of marketed medicines (UK)
A marketed portfolio of prescription medicines across multiple therapy areas with product listings and prescribing information available on national electronic medicines compendia.
Clinical trials disclosure platform
A public-facing clinical trials information platform listing trial registrations and outcomes for transparency and professional access.
Services
Provision of non-promotional digital resources for primary care to identify and manage uncontrolled and suspected severe asthma, including clinical-system searches, alerts, referral templates, reporting functionality, and an associated action-learning programme for implementation support.
Telephone and email medical information service staffed on business days to answer enquiries from healthcare professionals and patients about medicines, safety and device technique, and to provide a reporting route for suspected adverse events.
Competitive grant provision and partnership development to support projects that advance clinical practice in priority therapy areas and address health inequalities, evaluated via committee review.
Dedicated supply chain portal and coordination services for availability, ordering and delivery of medicines to pharmacies and hospitals.
Provision of press releases, corporate articles, designated media contacts and management of public social channels under community guidelines that set content restrictions and moderation policies.
Provision of non-promotional digital resources for primary care to identify and manage uncontrolled and suspected severe asthma, including clinical-system searches, alerts, referral templates, reporting functionality, and an associated action-learning programme for implementation support.
Telephone and email medical information service staffed on business days to answer enquiries from healthcare professionals and patients about medicines, safety and device technique, and to provide a reporting route for suspected adverse events.
Competitive grant provision and partnership development to support projects that advance clinical practice in priority therapy areas and address health inequalities, evaluated via committee review.
Dedicated supply chain portal and coordination services for availability, ordering and delivery of medicines to pharmacies and hospitals.
Provision of press releases, corporate articles, designated media contacts and management of public social channels under community guidelines that set content restrictions and moderation policies.
Expertise Areas
- Clinical trial management and transparency
- Pharmacovigilance and medical information
- Adverse event triage from public channels
- Large-scale pharmaceutical manufacturing
Key Technologies
- Clinical trials registry and disclosure platforms
- EHR data extraction and clinical-system queries
- Population health analytics and dashboards
- Real-world evidence (RWE) study methods
News & Updates
Working in partnership towards a carbon-free future in asthma care
AstraZeneca UK collaborates to create a greener NHS and improve asthma outcomes.
A brighter future for healthcare
UK President Tom Keith-Roach discusses collaboration to restore healthcare excellence.
AstraZeneca in UK impact report 2024
Details AstraZeneca's contribution to the UK economy, society, and sustainability goals.
AstraZeneca UK’s commitment to sustainability and health equity
Overview of AstraZeneca UK's efforts in climate action, reducing health inequalities, and community investment.
Decarbonising healthcare pathways in the UK
Initiatives like SENTINEL and SABINA CARBON study demonstrate AstraZeneca's efforts to reduce emissions in respiratory care.
AstraZeneca’s purpose-led partnerships in the UK
Collaborations with NHS, government, and charities to improve health outcomes and support innovation.
Working in partnership towards a carbon-free future in asthma care
AstraZeneca UK collaborates to create a greener NHS and improve asthma outcomes.
A brighter future for healthcare
UK President Tom Keith-Roach discusses collaboration to restore healthcare excellence.
AstraZeneca in UK impact report 2024
Details AstraZeneca's contribution to the UK economy, society, and sustainability goals.
AstraZeneca UK’s commitment to sustainability and health equity
Overview of AstraZeneca UK's efforts in climate action, reducing health inequalities, and community investment.
Decarbonising healthcare pathways in the UK
Initiatives like SENTINEL and SABINA CARBON study demonstrate AstraZeneca's efforts to reduce emissions in respiratory care.
AstraZeneca’s purpose-led partnerships in the UK
Collaborations with NHS, government, and charities to improve health outcomes and support innovation.